A standout was the opening of our new BSL-3 Facility, boosting our research capabilities. We’ve also made significant strides in monoclonal antibody production, with scaling techniques showcased at key venues like I4ID2024 in Lyon.
Takis was also selected for the IPCEI “Med4Cure” project, focusing on vaccines and gene therapies, including developing treatments for COVID-19 and cancer.
We’ve laid the groundwork for greater international presence, engaging with the U.S. and Chilean Embassies for cross-border collaborations.
Nationally, we led Rome Technopole’s Flagship Project 7 alongside public and private institutions.
Our COO, Emanuele Marra, joined the Pharmaceutical and Biomedical board of Unindustria, reflecting our influence in Italy’s industrial and scientific sectors.
Finally, we even changed our logo!
Heartfelt thanks to our clients, partners, collaborators, and supporters.
Wishing everyone a joyous holiday season and a successful New Year!
